Simpson Thacher recently represented the initial purchasers in connection with an offering of Notes by Roche Holdings, Inc. (“Roche”). The offering consisted of a Rule 144A and Regulation S offering of U.S.$875,000,000 aggregate principal amount of 4.790% notes due 2029, U.S.$750,000,000 aggregate principal amount of 4.909% notes due 2031, U.S.$1,250,000,000 aggregate principal amount of 4.985% notes due 2034 and U.S.$1,000,000,000 aggregate principal amount of 5.218% notes due 2054 (together, the “Notes”). The offering closed on March 8, 2024.
The net proceeds from the issue of the Notes will be used for general corporate purposes, including, among others, mergers and acquisitions, refinancing of short-term debt and regular debt maturities, payments of dividends and for potential early redemptions or mandatory prepayment events. The Roche Group is one of the world’s leading suppliers of in vitro diagnostics, one of the world’s largest biotech companies and a leading provider of cancer treatment drugs worldwide.
The Simpson Thacher team included Mark Brod, Alexander Yeagley and Mark Marzziotti (Capital Markets); Vanessa Burrows and Nawa Lodin (Healthcare); Michael Isby (Environmental); Marisa Geiger, Bobbie Burrows and Siak Goh (IP/Data Privacy); and Jonathan Cantor and Michael Leitner (Tax).